Caribou Biosciences
CRBU
124 hedge funds and large institutions have $59.6M invested in Caribou Biosciences in 2025 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 28 increasing their positions, 36 reducing their positions, and 14 closing their positions.
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
52% more call options, than puts
Call options by funds: $343K | Put options by funds: $225K
6% more funds holding
Funds holding: 117 → 124 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.17% less ownership
Funds ownership: 39.9% → 39.73% (-0.17%)
22% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 36
32% less capital invested
Capital invested by funds: $87M → $59.6M (-$27.4M)
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$1.8M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$1.59M |
| 3 |
BlackRock
New York
|
+$1.43M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.23M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$997K |
Top Sellers
CRBU Hedge Fund Activity: Q4 2025 in Review
124 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q4 2025, worth a combined $59.6M — down 32% from $87M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CRBU positions and 14 closed out — a net gain of 11 holders — while 28 added to existing stakes and 36 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.8M. The largest seller was Millennium Management, cutting an estimated $5.14M.
- 124 institutional investors held Caribou Biosciences (CRBU) as of Q4 2025, up from 117 in Q3 2025.
- Funds reported $59.6M of Caribou Biosciences stock for Q4 2025, down 32% quarter-over-quarter.
- 25 funds opened new Caribou Biosciences positions in Q4 2025 and 14 closed out, a net change of +11 holders.
- The largest Caribou Biosciences buyer in Q4 2025 was Renaissance Technologies, an estimated $1.8M added.
- The largest Caribou Biosciences seller in Q4 2025 was Millennium Management, an estimated $5.14M sold.
Based on aggregated 13F filings for Q4 2025.